CY1117547T1 - Ενωση πυραζολοκινολινης - Google Patents

Ενωση πυραζολοκινολινης

Info

Publication number
CY1117547T1
CY1117547T1 CY20161100451T CY161100451T CY1117547T1 CY 1117547 T1 CY1117547 T1 CY 1117547T1 CY 20161100451 T CY20161100451 T CY 20161100451T CY 161100451 T CY161100451 T CY 161100451T CY 1117547 T1 CY1117547 T1 CY 1117547T1
Authority
CY
Cyprus
Prior art keywords
bladder
pde9
inhibitory activity
compound
dysuria
Prior art date
Application number
CY20161100451T
Other languages
English (en)
Inventor
Hiroyuki Kaizawa
Hirofumi Yamamoto
Kazunori Kamijo
Mari Sugita
Ryushi Seo
Satoshi Yamamoto
Atsushi Ukai
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of CY1117547T1 publication Critical patent/CY1117547T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Για παροχή μίας ένωσης η οποία έχει ΡDΕ9-ανασταλτική δραστικότητα και είναι χρήσιμη ως ένα δραστικό συστατικό ενός παράγοντα για αντιμετώπιση και/ή πρόληψη υπερδραστήριας ουροδόχου κύστης, δυσουρίας, νόσου της ουροδόχου κύστης και του ουροποιητικού συστήματος, και των παρόμοιων. [Λύση] Οι εφευρέτες της παρούσας εφεύρεσης μελέτησαν ενώσεις οι οποίες έχουν ΡDΕ9-ανασταλτική δραστικότητα και είναι χρήσιμες ως δραστικά συστατικά παραγόντων για αντιμετώπιση και/ή πρόληψη υπερδραστήριας ουροδόχου κύστης, δυσουρίας, νόσου της ουροδόχου κύστης και του ουροποιητικού συστήματος, και των παρόμοιων, και τελειοποίησαν την παρούσα εφεύρεση επιβεβαιώνοντας ότι οι ενώσεις πυραζολοκινολίνης έχουν PDE9-ανασταλτική δραστικότητα. Η ένωση πυραζολοκινολίνης της παρούσας εφεύρεσης έχει ΡDΕ9-ανασταλτική δραστικότητα και μπορεί να χρησιμοποιηθεί ως ένας παράγοντας για πρόληψη και/ή αντιμετώπιση υπερδραστήριας ουροδόχου κύστης, δυσουρίας, νόσου της ουροδόχου κύστης και του ουροποιητικού συστήματος, και των παρόμοιων.
CY20161100451T 2010-09-07 2016-05-24 Ενωση πυραζολοκινολινης CY1117547T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010200403 2010-09-07
EP11823618.1A EP2615089B1 (en) 2010-09-07 2011-09-07 Pyrazoloquinoline compounds

Publications (1)

Publication Number Publication Date
CY1117547T1 true CY1117547T1 (el) 2017-04-26

Family

ID=45810740

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100451T CY1117547T1 (el) 2010-09-07 2016-05-24 Ενωση πυραζολοκινολινης

Country Status (18)

Country Link
US (1) US8822448B2 (el)
EP (1) EP2615089B1 (el)
JP (1) JP5888237B2 (el)
KR (1) KR101860583B1 (el)
CN (1) CN103097383B (el)
BR (1) BR112013005444B1 (el)
CA (1) CA2810696C (el)
CY (1) CY1117547T1 (el)
DK (1) DK2615089T3 (el)
EA (1) EA023493B1 (el)
ES (1) ES2583528T3 (el)
HR (1) HRP20160473T1 (el)
HU (1) HUE028038T2 (el)
MX (1) MX2013002584A (el)
PL (1) PL2615089T3 (el)
RS (1) RS54834B1 (el)
SI (1) SI2615089T1 (el)
WO (1) WO2012033144A1 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2573073T3 (pl) * 2011-09-26 2015-04-30 Sanofi Sa Pochodne pirazolochinolinonu, ich wytwarzanie i ich zastosowanie terapeutyczne
US9169246B2 (en) * 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
RU2605096C2 (ru) * 2011-10-07 2016-12-20 ЭЙСАЙ АрЭНДДи МЕНЕДЖМЕНТ КО., ЛТД. Пиразолохинолиновое производное
CN102786525B (zh) 2012-08-08 2014-12-17 中山大学 N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
SG11201507733YA (en) 2013-04-05 2015-10-29 Eisai R&D Man Co Ltd Pyridinylpyrazoloquinoline compound
CA2907971C (en) * 2013-04-05 2020-12-29 Eisai R&D Management Co., Ltd. Salt of pyrazoloquinoline derivative, and crystal thereof
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AR102849A1 (es) * 2015-03-09 2017-03-29 Astellas Pharma Inc Compuesto de piridina bicíclica
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2018276565A1 (en) 2017-06-01 2019-11-07 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
SG10202113199RA (en) 2017-06-01 2021-12-30 Eisai R&D Man Co Ltd Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
RU2019135261A (ru) 2017-06-01 2021-07-09 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция, содержащая ингибитор pde9
BR112019023552A2 (pt) 2017-06-01 2020-06-02 Eisai R&D Management Co., Ltd. Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina
IL312114A (en) 2021-10-14 2024-06-01 Incyte Corp Quinoline compounds as Kras inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192768A (en) 1990-09-14 1993-03-09 Kyowa Hakko Kogyo Co., Ltd. Pyrazoloquinoline derivatives
JPH05132484A (ja) * 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
KR20040053210A (ko) 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
NZ541232A (en) 2003-01-09 2008-02-29 Astellas Pharma Inc Pyrrolopyridazine derivatives
TW200508233A (en) 2003-05-29 2005-03-01 Millennium Pharm Inc Chk-1 inhibitors
JP2006045118A (ja) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
ES2526701T3 (es) 2005-06-14 2015-01-14 Aska Pharmaceutical Co., Ltd. Derivado de tienopirimidina
US7671069B2 (en) 2006-03-30 2010-03-02 Chemocentryx, Inc. Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7
AU2007282678B2 (en) 2006-08-08 2012-09-27 Aska Pharmaceutical Co., Ltd. Quinazoline derivative
ES2536906T3 (es) 2006-12-13 2015-05-29 Aska Pharmaceutical Co., Ltd. Derivado de quinoxalina
CN101557826A (zh) 2006-12-13 2009-10-14 Aska制药株式会社 泌尿***疾病的治疗药
JP4579346B2 (ja) 2007-05-11 2010-11-10 ファイザー・インク アミノ複素環式化合物
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
NZ590788A (en) 2008-09-08 2012-11-30 Boehringer Ingelheim Int Pyrazolopyrimidines and their use for the treatment of cns disorders
US9259564B2 (en) 2009-01-22 2016-02-16 Avent, Inc. Enteral feeding assembly with lock assembly
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物

Also Published As

Publication number Publication date
EP2615089A1 (en) 2013-07-17
SI2615089T1 (sl) 2016-08-31
JPWO2012033144A1 (ja) 2014-01-20
PL2615089T3 (pl) 2016-10-31
EP2615089A4 (en) 2014-01-01
EA201390353A1 (ru) 2013-08-30
EP2615089B1 (en) 2016-04-27
ES2583528T3 (es) 2016-09-21
CA2810696A1 (en) 2012-03-15
CN103097383A (zh) 2013-05-08
JP5888237B2 (ja) 2016-03-16
CA2810696C (en) 2018-09-18
EA023493B1 (ru) 2016-06-30
HRP20160473T1 (hr) 2016-07-29
BR112013005444A2 (pt) 2017-09-19
MX2013002584A (es) 2013-04-29
RS54834B1 (sr) 2016-10-31
US20130225553A1 (en) 2013-08-29
CN103097383B (zh) 2015-09-16
HUE028038T2 (en) 2016-11-28
KR20130106358A (ko) 2013-09-27
KR101860583B1 (ko) 2018-05-23
BR112013005444B1 (pt) 2019-07-09
US8822448B2 (en) 2014-09-02
DK2615089T3 (en) 2016-06-06
WO2012033144A1 (ja) 2012-03-15

Similar Documents

Publication Publication Date Title
CY1117547T1 (el) Ενωση πυραζολοκινολινης
CY1122984T1 (el) Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
PH12017501306A1 (en) Inhibitors of histone demethylases
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
EA201270566A1 (ru) Противомикробные соединения и способы их получения и применения
EA201100873A1 (ru) Пиридилоксииндолы - ингибиторы vegf-r2 и их применение для лечения заболевания
NO20092444L (no) Heteroarylamidderivater
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
BRPI1009860A2 (pt) composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
MX2015010829A (es) Compuestos terapeuticos y sus usos.
CN107406464A8 (zh) 精氨酸酶抑制剂及其治疗用途
MX2013003638A (es) Tratamiento en combinacion para rosacea.
WO2012158672A3 (en) Compounds for use in treatment of mucositis
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
BR112015026840A2 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto, e, método prevenir ou tratar hiperfosfatemia
BRPI0920251A2 (pt) composto, composição famacêutica, formulação, métodos para preparar o composto, um sal farmaceuticamente aceitável, para inibir o crescimento de um micróbio, para tratar um mamífero tendo uma infecção microbiana, e, uso de um composto.
MX2019004484A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
MX2009011819A (es) Formulaciones de aminoacido n-halogenado.
UY31058A1 (es) Formulaciones de aminoacido n-halogenado con compuestos antiinflamatorios
MX2009011817A (es) Formulaciones de aminoacido n-halogenado que contienen acido alifatico.